BriaCell Therapeutics Corp. (BCTX, BCTXW) is down by 4.71 percent during Monday morning trading, following the announcement of a clinical response in a metastatic breast cancer patient treated with its personalized off-the-shelf immunotherapy, Bria-OTS. Despite the resolution of a lung metastasis in one patient, the broader implications of the treatment have overshadowed the news.
BCTX is currently trading at $4.78, down 4.71 percent or $0.23 on the Nasdaq. The stock has experienced notable fluctuations today, with a high of $7.87 and a low of $5.18, as investors reacted cautiously to the announcement. The total volume for the day is 13.3 million shares, significantly higher than the average volume of 1.31 million.
Bria-OTS is still being tested in a Phase 1/2a dose escalation study for metastatic recurrent breast cancer, an experimental therapy that follows BriaCell's lead candidate, Bria-IMT, which is currently undergoing a pivotal Phase 3 study for metastatic breast cancer.
For comments and feedback contact: editorial@rttnews.com
Business News
December 19, 2025 15:10 ET U.S. inflation data and interest rate decisions by major central banks were the highlights of this busy week for economics news flow. Employment data and survey results on the housing markets also gained attention in the U.S. In Europe, the European Central Bank and Bank of England announced their policy decisions and macroeconomic projections.